Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 123-131

  Silver, M R ^a   Geronemus, R ^b   Krause, M ^c   Chen, C Y ^d   Kewalramani, R ^d   Stehman Breen, Catherine ^d  

^a METROHEALTH MEDICAL CENTER   (United States)

^b South Florida Nephrology Associates   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d AMGEN INC   (United States)

Author keywords

Anemia; Chronic kidney disease; Darbepoetin alfa; Erythropoietin; Extended dosing

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; DRUG DERIVATIVE; ERYTHROPOIETIN;

AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BIOASSAY; BLOOD CHEMISTRY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIALYSIS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; MIDDLE AGED;

AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 64249167566     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802594818     Document Type: Article

References (31)

1. Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000;53:S2-8
2. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-630
3. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-812
4. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-962
5. Astor BC, Coresh J, Heiss G, et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006;151:492-500
6. Gerson A, Hwang W, Fiorenza J, et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004;44:1017-1023
7. Goicoechea M, de Vinuesa SG, Gomez-Campdera F, et al. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl 2005;67(Suppl 93):S35-8
8. Jurkovitz CT, Abramson JL, Vaccarino LV, et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003;14:2919-2925
9. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134
10. Odden MC, Whooley MA, Shlipak MG. Association of chronic kidney disease and anemia with physical capacity: the heart and soul study. J Am Soc Nephrol 2004;15:2908-2915
11. Perlman RL, Kiser M, Finkelstein F, et al. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. Semin Dial 2003;16:418-423
12. National Kidney Foundation. K/DOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530
13. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084
14. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098
15. Gouva C, Nikolopoulos P, Ioannidis JP, et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-760
16. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-312
17. Abu-Alfa AK, Sloan L, Charytan C, et al. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 2008;24:1091-1100
18. Alexander M, Kewalramani R, Agodoa I, et al. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 2007;23:2997-3008
19. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-554
20. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006;47:738-750
21. Pappas KD, Gouva CD, Katopodis KP, et al. Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22:37-44
22. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799-811
23. Hertel JE, Locay HR, Scarlata DS, et al. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006;81:1188-1194
24. Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23:106-111
25. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453-460
26. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000;11:0828
27. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001;10:785-792
28. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: John Wiley, 1973
29. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182-238
30. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007
31. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002;17(Suppl 11):44-46